Table 2
From the following article
Albinterferon 
-2b: a genetic fusion protein for the treatment of chronic hepatitis C
G Mani Subramanian, Michele Fiscella, Araba Lamousé-Smith, Stefan Zeuzem & John G McHutchison
Nature Biotechnology 25, 1411 - 1419 (2007) Published online: 7 December 2007
doi:10.1038/nbt1364
Table 2. Clinical studies with albumin-fusion products
| Albumin-fusion products | Fusion partner MW (kDa) | Development-stage | Indication |
|---|---|---|---|
| Alb-growth hormone (GH) | 22 | Phase 1/2 | Growth hormone deficiency |
| Alb-granulocyte colony-stimulating factor (GCSF) | 19.6 | Phase 1/2 | Neutropenia |
| Alb-interferon (IFN-) | 19.2 | Phase 3 | Chronic hepatitis C |
| Alb-interleukin 2 (IL2) | 15.5 | Phase 1/2 | Malignancy |
| Alb-glucagon-like peptide 1 (GLP-1) | 3.8 | Phase 1/2 | Diabetes mellitus |
Alb- -natriuretic peptide (BNP) | 3.5 | Phase 1/2 | Congestive heart failure |